Blind patients are regaining vision thanks to optogenetics. Fresh 2025 clinical results show meaningful improvements for people with retinitis pigmentosa and Stargardt disease — better mobility, object recognition, and visual function after a single treatment. Even bigger: AI targeted light is now enabling real-time breakthroughs in Parkinson’s diagnosis and therapy. Neurotech isn’t coming. It’s here. That’s why
Optogenetics.ai is the perfect premium domain for this moment — light-controlled biology, AI-powered brain interfaces, and the exploding $2.8B neurotherapy market. Built for the startups, labs, and visionaries ready to lead. More than a domain. It’s the brand for the future of the brain. What’s your take — where do you see optogenetics heading next? Reply below or DM if you’re interested.
#NeuroTech #Optogenetics #AI #Neuroscience